GLP-1 Medications Like Ozempic Show Promise for Weight Loss, But Funding Concerns Loom
A new series of reviews highlights the significant weight loss potential of GLP-1 medications, but also raises critical questions about the influence of pharmaceutical companies on research findings. Commissioned by the World Health Organization (WHO), these analyses are poised to shape upcoming global guidelines for utilizing these drugs in obesity treatment.
The Cochrane reviews examined three prominent medications – tirzepatide (Mounjaro and Zepbound), semaglutide (Ozempic, Wegovy, and Rybelsus), and liraglutide (Victoza and Saxenda) – all classified as GLP-1 receptor antagonists. Across the board, each drug demonstrated greater weight loss compared to a placebo, though researchers identified gaps in understanding long-term health outcomes, potential side effects, and the impact of industry funding.
From Diabetes Treatment to Obesity Therapy
Initially developed in the mid-2000s to treat type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have expanded their therapeutic role. For individuals with diabetes, particularly those with heart or kidney disease, these medications have proven effective in improving blood sugar levels, reducing cardiovascular and renal complications, supporting weight management, and lowering the risk of premature death.
More recently, researchers have investigated the efficacy of GLP-1 receptor agonists specifically for obesity. These drugs mimic the action of a natural hormone, slowing digestion and promoting feelings of fullness. In the United Kingdom, they are currently approved for weight management when combined with a reduced-calorie diet and exercise for individuals with obesity or those who are overweight and have weight-related health conditions.
How Much Weight Loss Do GLP-1 Drugs Produce?
The reviews revealed substantial weight loss over one to two years with all three drugs when compared to placebo, with benefits continuing as long as treatment is maintained. Tirzepatide, administered weekly, resulted in an average weight reduction of approximately 16% after 12 to 18 months. Data from eight randomized controlled trials involving 6,361 participants suggests this level of weight loss could be sustained for up to 3.5 years, although long-term safety data remains limited.
Semaglutide, also injected weekly, yielded an average weight loss of roughly 11% after 24 to 68 weeks. Findings from 18 randomized controlled trials encompassing 27,949 participants indicate the effect can persist for up to two years. Participants taking semaglutide were more likely to experience at least 5% body weight loss, but also reported higher rates of mild-to-moderate gastrointestinal side effects.
Liraglutide, a daily injection, demonstrated more modest results, with average weight loss of about 4-5% based on 24 trials involving 9,937 participants. Nevertheless, a greater proportion of individuals achieved meaningful weight loss compared to those receiving a placebo. Evidence extending beyond two years of treatment was limited.
Notably, researchers found little to no difference between the GLP-1 drugs and placebo when it came to major cardiovascular events, quality of life, or mortality. Side effects, particularly nausea and digestive issues, were more common with the medications, leading some participants to discontinue treatment.
“These drugs have the potential to bring about substantial weight loss, particularly in the first year,” stated a senior researcher. “It’s an exciting moment after decades of unsuccessful attempts to find effective treatments for people living with obesity.”
Concerns About Industry Funding and Access
A significant proportion of the studies included in the reviews were funded by the manufacturers of these drugs. In many instances, these companies were heavily involved in the design, execution, analysis, and reporting of the trials. This level of involvement raises concerns about potential conflicts of interest and underscores the need for more independent research.
The authors also emphasized that broader adoption of GLP-1 medications must consider social and economic factors, including cost, insurance coverage, and overall accessibility. Without careful planning, expanded use could exacerbate existing health disparities among individuals with obesity. Currently, the high cost of semaglutide and tirzepatide restricts access, while liraglutide has become more affordable due to the expiration of its patent and the availability of generic versions. Semaglutide’s patent is also slated to expire in 2026.
Furthermore, the majority of trials were conducted in middle- and high-income countries, with limited representation from regions like Africa, Central America, and Southeast Asia. Researchers stress the importance of studying these drugs in diverse global settings, as body composition, dietary habits, and health behaviors vary significantly across populations.
“We need more data on the long-term effects and other outcomes related to cardiovascular health, particularly in lower-risk individuals,” explained a co-lead researcher from the Universidad de Valparaíso, Chile. “Weight regain after stopping treatment may affect the long-term sustainability of the observed benefits. More independent studies from a public health perspective are needed.”
Long-Term Evidence Needed for Future Guidelines
The reviews conclude that longer-term, independently funded studies are essential for informing both medical practice and public health policy. A more comprehensive understanding of sustained benefits and risks will be crucial in defining the role of GLP-1 receptor agonists in long-term weight management.
These findings, commissioned by the World Health Organization, will directly inform the development of new WHO guidelines regarding the use of GLP-1 receptor agonists for obesity treatment.
